News | PET-CT | June 09, 2017

Toshiba Medical’s New Celesteion PET/CT Improves Resolution, Reconstruction

Offers Patient Comfort and Safety

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients.

Oncologists have access to advanced imaging technologies for excellent cancer patient care with the new Celesteion PUREViSION Edition PET/CT system from Toshiba Medical, a Canon Group company. The newest edition of Celesteion allows for ease and efficiency in PET/CT, CT simulation and diagnostic CT exams, to help diagnose and treat oncology patients. The system’s patient-centered design can help deliver a safe and comfortable experience, facilitating better patient compliance.

The Celesteion PUREViSION Edition presents a significant advancement in PET/CT resolution and reconstruction. Offering 70 cm true field-of-view, as well as Toshiba Medical’s SUREFLiGHT reconstruction technology, including Point Spread Function and Time of Flight techniques, the system offers oncologists sharp images and high contrast for improved visualization of small tumors throughout the body. The system’s PUREViSION 16-row CT detector assists in acquiring high-quality CT images, while SEMARTM helps reduce artifacts caused by metal implants, allowing providers to view more clinical information.

Prioritizing patient comfort, the Celesteion PUREViSION Edition features an industry-leading 90 cm wide CT bore that creates a sense of openness to put patients at ease and offers versatile positioning for optimal treatment planning. Ensuring clinicians don’t have to choose between efficiency and safety, the system also comes standard with AIDR 3D iterative dose reduction technology.

“We developed the Celesteion PUREViSION Edition with our customers’ needs in mind,” said Dominic Smith, senior director, CT, PET/CT, and MR Business Units, Toshiba America Medical Systems, Inc. “Accuracy is everything when treating oncology patients and Toshiba Medical is committed to providing our customers with the high-quality imaging solutions they require to provide efficient, effective patient care.”

Toshiba Medical will showcase the Celesteion PUREViSION Edition at this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Denver, June 10–14, 2017.

For more information: www.medical.toshiba.com

Related Content

Sponsored Content | Videos | Pediatric Imaging | February 22, 2018
FUJIFILM Medical Systems U.S.A., Inc. and FUJIFILM SonoSite Inc., are offering a full-suite pediatric solutions...
Sponsored Content | Videos | Flat Panel Displays | February 21, 2018
This 5 megapixel, high-brightness color monitor has the high-definition display necessary for breast imaging.
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Sponsored Content | Videos | Imaging | February 15, 2018
David Widmann, president and CEO of Konica Minolta, looks at what the future of healthcare can bring to its customers,...
Sponsored Content | Videos | Artificial Intelligence | February 15, 2018
ITN Contributing Editor Greg Freiherr offers an overview of artificial intelligence advances at the Radiological Soci
Videos | Enterprise Imaging | February 13, 2018
ITN Contributing Editor Greg Freiherr offers an overview of enterprise imaging advances at the Radiological Society of...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Feature | Digital Radiography (DR) | January 31, 2018 | By Jeff Zagoudis
If there was a theme to digital radiography (DR) advances in 2017, it might have been “upgrade now or be left behind.”...
MedCurrent Rolls Out OrderWise Clinical Decision Support Platform With iRefer Guidelines
Technology | Clinical Decision Support | January 29, 2018
Primary care providers and hospital doctors around the world can now access the imaging referral guidelines from the U....
Overlay Init